Merck taps Italian CRO IRBM for peptide drug development

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/scyther5)
(Image: Getty/scyther5)

Related tags: Merck & co, MSD, Peptide synthesis, Peptides, Contract research, Contract research organization, CRO

IRBM and Merck have signed a new agreement in the peptide therapeutics area through which the Italian CRO will identify potential peptide leads for a specific Merck target.

The Italy-headquartered contract research organization (CRO) IRBM has been collaborating with Merck & Co., Inc. (known as MSD outside the US and Canada) since 2010.

IRBM will be applying its capabilities in phage display peptide library design and screening, as well as in chemical peptide synthesis and optimization, according to the company.

“At MSD, evaluating the potential of peptide-based therapeutic candidates is a key part of our discovery strategy,” ​said Emma Parmee, VP of global discovery chemistry, MSD, ​in a press release.

“Our R&D peptide group have extensive expertise to help deliver high quality peptide drugs for a wide variety of therapeutic indications,” ​said Carlo Toniatti, CSO at IRBM. “We are thrilled to be collaborating on this project as part of our mission to advance impactful agents into the clinic.”

Related news

Show more

Related products

show more

QPS: Global Custom-Built Research Services

QPS: Global Custom-Built Research Services

QPS | 16-Dec-2019 | Product Brochure

Performing complex studies in special populations with remarkable agility. Clinical research just got better with QPS’ Custom-Built Research Services....

Validating The Simoa Technology

Validating The Simoa Technology

Frontage Laboratories | 01-Oct-2019 | Technical / White Paper

Frontage is the first and only laboratory to validate Quanterix’ Simoa HD1 Analyzer for performing immunoassays. Most of the advanced instruments used...

Related suppliers

Follow us


View more